Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 11/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28566167 | 0.74 | CHRNB2 (0.33) | SSTR4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL29244684 | 0.74 | IRAK4 (0.40) | IRAK4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL3830342 | 0.73 | L3MBTL1 (0.37) | SSTR4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL14690630 | 0.73 | — | — | |
| SCHEMBL14690632 | 0.73 | — | — | |
| SCHEMBL6618689 | 0.72 | CHRNB2 (0.35) | SSTR4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL18840022 | 0.72 | L3MBTL1 (0.36) | SSTR4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1531791 | 0.71 | SSTR4 (0.32) | SSTR4L3MBTL1SSTR1 | |
| SCHEMBL28567924 | 0.71 | — | — | |
| SCHEMBL22418656 | 0.71 | BCHE (0.33) | SSTR4CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239959-A | Cyclopropane TLR7 and 8 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118239926-A | TLR7 and 8 inhibitors, preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2022-12-08 | — | — | US | disclosed |
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021035101-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | TARDBP, TDP1, TDP2 | SSTR4 4625/4885IRAK4 3280/4885CHRNB2 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.